Welcome to our dedicated page for BRTXD news (Ticker: BRTXD), a resource for investors and traders seeking the latest updates and insights on BRTXD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BRTXD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BRTXD's position in the market.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) has announced a public offering of 2,300,000 units, priced at $10.00 each, consisting of common stock and warrants. The offering is projected to raise gross proceeds of $23 million. This marks a significant milestone as the company's common stock will begin trading on The Nasdaq Capital Market under the ticker symbol 'BRTX' from November 5, 2021. The offering is expected to close around November 9, 2021, and includes an option for underwriters to purchase up to 345,000 additional shares. Funds raised aim to enhance the company’s financial position.
BioRestorative Therapies (BRTX) announced a 1-for-4,000 reverse stock split to facilitate its planned listing on The Nasdaq Capital Market. The split is effective from October 27, 2021, with the temporary ticker symbol BRTXD. Following the split, outstanding shares will decrease from approximately 3.49 billion to 872,211. The company believes this action meets Nasdaq's initial listing requirements, enhancing its appeal to institutional investors and access to capital.
